Cecal Perforation in a COVID-19 Patient Treated with Tocilizumab: A Case Report
Victor Dominguez Prieto Cecilia Meliga Sara Rosenstone Siyuan Qian Zhang Manuel Escanciano Escanciano Felipe Velez Pinto Sergio Hernandez Villafranca Sara Gonzalez Soares Javier Barambio Buendia Miguel Leon Arellano Damian Garcia Olmo Ricardo Pardo Garcia Hector Guadalajara Labajo
Corresponding AuthorVictor Dominguez Prieto
Surgery Department, Hospital Universitario Fundacion Jimenez Diaz, Madrid, Spain
A B S T R A C T
Tocilizumab is a monoclonal antibody against the interleukin-6 receptor. Gastrointestinal perforation has been associated with Tocilizumab treatment. In the absence of specific antiviral drugs, Tocilizumab is currently being used as a treatment option in patients with severe COVID-19 pneumonia. This is being based on the implication of interleukin-6 in the aberrant host immune response that characterizes the disease and initiates patients' lung damage. Herein we present the case of a cecal perforation in a patient treated with Tocilizumab for COVID-19. In such context, we expect that there may be an increase in the incidence of gastrointestinal perforation related to Tocilizumab.
Article TypeCase Report
Publication historyReceived: Tue 27, Jul 2021
Accepted: Wed 11, Aug 2021
Published: Thu 09, Sep 2021
Copyright© 2021 Victor Dominguez Prieto. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Hosting by Science Repository.